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Abstract
Atypical cannabinoid compounds O-1602 and O-1918 are ligands for the putative 
cannabinoid receptors G protein-coupled receptor 55 and G protein-coupled receptor 
18. The role of O-1602 and O-1918 in attenuating obesity and obesity-related pathologies 
is unknown. Therefore, we aimed to determine the role that either compound had on 
body weight and body composition, renal and hepatic function in diet-induced obesity. 
Male Sprague–Dawley rats were fed a high-fat diet (40% digestible energy from lipids) 
or a standard chow diet for 10 weeks. In a separate cohort, male Sprague–Dawley 
rats were fed a high-fat diet for 9 weeks and then injected daily with 5 mg/kg O-1602, 
1 mg/kg O-1918 or vehicle (0.9% saline/0.75% Tween 80) for a further 6 weeks. Our 
data demonstrated that high-fat feeding upregulates whole kidney G protein receptor 
55 expression. In diet-induced obesity, we also demonstrated O-1602 reduces body 
weight, body fat and improves albuminuria. Despite this, treatment with O-1602 resulted 
in gross morphological changes in the liver and kidney. Treatment with O-1918 improved 
albuminuria, but did not alter body weight or fat composition. In addition, treatment with 
O-1918 also upregulated circulation of pro-inflammatory cytokines including IL-1α, IL-2, 
IL-17α, IL-18 and RANTES as well as plasma AST. Thus O-1602 and O-1918 appear not to 
be suitable treatments for obesity and related comorbidities, due to their effects on organ 
morphology and pro-inflammatory signaling in obesity.
Introduction
The prevalence of obesity is increasing worldwide and is 
an established risk factor for a number of comorbidities 
including diabetes, hypertension, chronic kidney disease 
and fatty liver disease (1, 2). The significant social and 
financial burden associated with obesity has warranted 
the investigation of therapeutic targets to reduce 
the pathophysiological changes observed in obesity. 
One pharmacological target currently being investigated 
for obesity and associated comorbidities is the 
endocannabinoid system (3). In obesity, the endogenous 
endocannabinoid anandamide (AEA) promotes 
appetite and reduces energy expenditure through the 
activation of cannabinoid receptor 1 (CB1) (4). AEA and 
tetrahydrocannabinol (THC) binds with a similar affinity 
-18-0535
Key Words
 f cannabinoid
 f GPR55
 f GPR18
 f high-fat diet
 f O-1602
 f O-1918
 f obesity
Endocrine Connections
(2019) 8, 203–216
ID: 18-0535
8 3
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-18-0535
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 06/06/2019 01:20:03AM
via free access
A C Simcocks et al. O-1602 and O-1918 in high-fat 
induced obesity
204
PB–14
8:3
to cannabinoid receptors CB1 and CB2 (5). Research into 
the dysregulated endocannabinoid system in obesity has 
been investigated for more than a decade (6, 7, 8).
One atypical cannabinoid derived from Cannabis 
sativa is cannabidiol (CBD). This compound has a number 
of physiological functions such as reducing inflammation 
and oxidative stress (9). A synthetic isomer of CBD is 
abnormal cannabidiol (Abn-CBD) (10). Both Abn-CBD 
and CBD have limited binding capacities to CB1 and 
CB2. Consequently, these compounds do not induce the 
psychotropic effects induced by THC (4). CBD has long 
lasting effects (up to 80 days) and has been used for the 
treatment of inflammatory pain and multiple sclerosis 
(MS) in mouse models (11). In humans CBD treatment 
safely and effectively reduces symptoms of pain and 
spasticity in MS patients (12). Additionally, both CBD 
and Abn-CBD mediate a potentially protective role in 
diabetes (13, 14). Although, in humans with T2DM, 
CBD does not have the same protective effects that are 
observed in diabetic animal and cell culture models 
(15, 16, 17). CBD also promotes a browning phenotype, 
lipolysis, thermogenesis and reduces lipogenesis in 
3T3-L1 adipocytes (18).
CBD and Abn-CBD have an affinity to putative 
cannabinoid receptors G protein-coupled receptor 55 
(GPR55) and G protein-coupled receptor 18 (GPR18) 
(9, 19, 20). O-1918, a synthetic compound similar to CBD, 
is a putative antagonist for GPR55 and an antagonist for 
GPR18 (20) or a biased agonist for GPR18 (21). Limited 
research has been conducted examining the potential 
therapeutic use of O-1918 in disease. In vitro, O-1918 
may be useful in promoting wound healing and bone 
regeneration, as treatment with O-1918 in mesenchymal 
stem cells increases migration in a concentration-
dependent manner via the p44/42 MAPK pathway (22). 
O-1918 may also mediate cardiovascular hemodynamics, 
as this compound can inhibit the hypotensive effects of 
Abn-CBD and AEA (23).
Conversely, O-1602 is a synthetic analog of Abn-CBD 
and is also a potent agonist for GPR55 (24) and a biased 
agonist for GPR18 (21). Using animal models, O-1602 
mediates a number of physiological effects including a 
reduction in pain (25) and inflammation (26), an inhibition 
in tumor growth (27), an inhibition of osteoclast formation 
in vitro (28), an inhibition of neutrophil migration (29) as 
well as regulating gastrointestinal motility (30). O-1602 
also has pro-inflammatory and pro-atherogenic effects 
which are thought to be mediated by GPR55 (31).
An acute, single dose treatment of O-1602 in rodents 
increased food intake, via reduced expression of the 
anorexigenic neuropeptide cocaine- and amphetamine-
regulated transcript (CART) (32). However, when lean 
rodents fed a standard chow diet were infused with O-1602 
for 7 days, an increase in adiposity was observed despite 
no alterations to weight gain, food intake or individual fat 
pad mass (32).
Thus, as O-1602 and O-1918 may be able to 
mediate a number of physiological processes including 
the metabolic regulation of weight and appetite, it is 
hypothesized that these compounds will have an effect 
on obesity. Therefore, this study aimed to determine the 
effects that treatment with either O-1602 or O-1918 had 
in a diet-induced obese (DIO) rat model. Specifically, 
the objective of the study was to examine the effects of 
O-1602 and O-1918 on body weight, food consumption, 
body composition, organ weights, blood pressure and 
blood glucose control in a high-fat obesity model. 
Furthermore, this study aimed to elucidate whether these 
compounds elicited changes to signaling pathways in 
organs known to be affected by the obese state, including 
the kidneys and liver.
Materials and methods
Animals
All animal studies were conducted in accordance with 
the National Institutes of Health’s Guide for the Care 
and Use of Laboratory Animals. All animal-experimental 
procedures were approved by The Florey Institute 
of Neuroscience and Mental Health Animal Ethics 
Committee (AEC 11-036 and AEC 09-050) and performed 
at the Howard Florey Institute (Parkville, Victoria, 
Australia). Seven-week-old male Sprague–Dawley rats 
were sourced from the Animal Resource Centre (Canning 
Vale, Western Australia). Sprague–Dawley rats were 
selected due to their ability to gain weight on a high-fat 
diet (HFD). This strain of rat also shows a diverse response 
in weight gain following consumption of a HFD with 
some Sprague–Dawley rats being obese resistant and some 
being predisposed to obesity. Following acclimatization 
to experimental conditions the rats (weight 322.0 g ± 31.7, 
prior to commencing the HFD) were individually 
housed in a plastic tube with a secure stainless steel lid 
(dimensions width 27.5 × length 41 × height 25.5 cm) 
(R.E. Walters, Sunshine, Melbourne, Victoria, Australia) 
in an environmentally controlled laboratory (ambient 
temperature 22–24°C) with a 12 h light/darkness cycle 
(07:00–19:00).
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High-fat feeding and chronic treatment with 
pharmacological compounds O-1602 or O-1918 in 
DIO model
A cohort of rats (n = 8 per group) were randomly assigned 
to either the HFD (containing 21% crude fat, 40% 
digestible energy from lipids; sourced from Specialty 
Feeds Ltd., Glen Forrest, Australia; Table 1) or a chow diet 
(containing 10% digestible energy from lipids; sourced 
from Barastoc Ltd., Melbourne, Victoria, Australia; 
Table 1) (33) for 10 weeks. The list of ingredients for the 
SCD and HFD are outlined in Table  1 and comparison 
nutritional composition of the SCD and HFD is shown in 
Table 2. In a separate cohort, rats were fed a HFD (33) for 
9 weeks. In this rat model, we have previously established 
that 9  weeks of DIO is sufficient to induce significant 
increases in body weight, body fat composition and 
blood pressure compared to standard chow lean controls 
(33). As the rats had a diverse response to the HFD, a 
group allocation was completed which matched animals 
according to weight, body composition, blood pressure, 
glucose tolerance and insulin sensitivity and the rats were 
then allocated to either DIO control (n = 11), DIO O-1602 
(n = 6), or DIO O-1918 (n = 9) groups. O-1918 and O-1602 
were sourced from Tocris Bioscience (Bristol, UK). Rats 
consuming a HFD, for a further 6 weeks were maintained 
on the HFD and treated daily with either a vehicle 0.9% 
isotonic saline solution containing 0.75% Tween 80 
(DIO + control), 5 mg/kg of O-1602 (DIO + O-1602) or 
1 mg/kg of O-1918 (DIO + O-1918) with compounds 
dissolved in the vehicle solution, and administered via 
intraperitoneal (ip.) injection. The dosages of O-1602 
and O-1918 were chosen based on previous literature 
demonstrating that the compound reduces colitis scores 
in a colitis model (34), and inhibits the hypotensive 
effects of Abn-CBD in mice (23), respectively. Access to 
food and water was maintained, ad libitum, throughout 
the duration of the study.
Following the conclusion of the pharmacological 
treatment period, rats were deeply anesthetized using 3% 
isoflurane (Abbott), skeletal muscles were extracted and 
then the rats were administered an ip. injection of sodium 
pentabarbitone (100 mg/kg; Virbac, Peakhurst, Australia) 
and killed via cardiac puncture. While the DIO 10 week 
group of rats were administered an ip. injection of sodium 
pentabarbitone and then killed via cardiac puncture. 
Organs including the heart, kidney, liver and adipose 
tissue fat pads were then removed postmortem, weighed 
individually and then the tissues were stored at −80°C for 
further analysis.
Physiological measurements
Body weight and food consumption of the rats were 
recorded daily throughout the experimental treatment 
period. Daily food consumption was determined by 
collecting and weighing food pellets remaining in the 
cage each day and ensuring that any visible spillage 
within the cage was also collected and weighed. Total 
body composition was measured at baseline (after 9 weeks 
of DIO), 3 weeks into treatment (after 12 weeks of DIO) 
and 6 weeks into treatment (at the 15 week conclusion 
of DIO) using an EchoMRI Whole Body Composition 
Analyzer (EchoMRI-900; EchoMRI, Houston, TX, USA) 
(33). Systolic and diastolic blood pressure measurements 
were obtained from conscious rats using a noninvasive 
tail-cuff method with volume pressure recording software 
CODA 2 (Kent Scientific, Torrington, CT, USA) (33) at 
baseline (after 9 weeks of DIO) and 6 weeks into treatment 
(at the 15  week conclusion of DIO). Glucose tolerance 
(2 g/kg glucose) and insulin sensitivity (0.75 U/kg insulin) 
tests were measured at baseline (after 8  weeks of DIO) 
and toward the end of the pharmacological treatment 
period 5  weeks into treatment (after 14  weeks of DIO). 
The glucose or insulin bolus used for the glucose tolerance 
test and insulin sensitivity test were administered using 
an ip. injection. Rats were fasted overnight for the glucose 
tolerance test and for two hours prior to commencing 
the insulin sensitivity test. Blood glucose in response to 
glucose and insulin was analyzed as delta area under the 
curve (delta AUC) using GraphPad Prism Software (33). 
To assess insulin sensitivity further the rate of glucose 
Table 1 Ingredients listed in diets.
High-fat diet (SF00-219) Standard chow diet
Casein (acid) Cereal grains and cereal 
by-products
Sucrose Legumes and legume 
by-products
Clarified butter (ghee) Vegetable protein meals
Cellulose Fats and oil
Wheat starch Vitamins
DL Methionine Minerals
Calcium carbonate Yucca schidigera extracts
Sodium chloride
AIN93 trace minerals
Potassium citrate
Potassium dihydrogen phosphate
Potassium sulfate
Choline chloride (75%)
SF00-219 vitamins or AIN93 vitamins
Cholesterol
Oxicap E2
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utilization KITT (%/m) = [(ln1 − ln2)/(t2 − t1)] × 100 (35, 36), 
the half-life of glucose t½ (min) = (0.693/KITT) × 100 
(36) and maximal decline of glucose (mmol/L) were 
also calculated.
Hydroxyproline analysis
To determine total collagen content and concentration 
from the heart and liver of rats subjected to DIO and 
treated with or without O-1602, a colorimetric-based 
hydroxyproline assay was utilized to measure fibrosis as 
previously described (37).
Renal measurements
Urine was collected over a 24 h period using a metabolic 
cage. Measurements of urinary albumin (ALPCO 
Diagnostics, Salem, NH, USA) and both urinary and 
plasma creatinine (Cayman Chemical Company, Ann 
Arbor, MI, USA) were determined using commercially 
available kits, according to the manufacturer’s instructions 
as previously described (33) and were evaluated at 
baseline and during the final week of the pharmacological 
intervention (pre- and posttreatment periods). Estimated 
creatinine clearance was measured once and was 
determined using blood collected at the experimental 
end point, and the final 24 h urine collection. Estimated 
creatinine clearance was determined using the formula 
(Urinary vol (mL/min) × urinary creatinine concentration 
(mg/dL))/plasma creatinine (mg/dL) and was adjusted for 
body weight. Histological analysis of the glomerular area 
and tubular cross-sectional diameter was imaged at 200× 
magnification (Carl Zeiss). Glomerular area and tubular 
diameter was measured using image analysis software 
(Axiovision 4.8; Carl Zeiss) (33).
Plasma analysis
Following cardiac puncture, blood was transferred 
into 10 mL Ethylenediaminetetraacetic acid (EDTA) 
BD Vacutainer tubes (McFarlene Medical, Surry Hills, 
Victoria, Australia) and kept on ice until samples were 
centrifuged at 4000 × g for 10 min at 4°C. The plasma 
layer was aspirated and stored until further analysis at 
−80°C. Plasma concentrations of transforming growth 
factor beta 1 (TGF-β1) (Promega), adiponectin (AdipoGen, 
Liestal, Switzerland), glucagon-like peptide 1 (GLP-1), 
ghrelin, leptin (Bioplex hormone immunoassay; Bio-Rad 
Laboratories), erythropoietin (EPO), growth regulated 
α protein/keratinocyte chemoattractant (GROC/KC), 
interferon gamma (IFN-γ), interleukin 1 alpha (IL-1α), 
interleukin 1 beta (IL-1β), monocyte chemotactic protein 
1 (MCP-1), interleukin 2 (IL-2), interleukin 4 (IL-4), 
interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 
10 (IL-10), interleukin 17 alpha (IL-17α), interleukin 
18 (IL-18), macrophage colony stimulating factor (MC-SF), 
macrophage inflammatory protein 3 alpha (MIP-3α), 
regulated upon activation of normal T-cells expressed and 
secreted (RANTES), tumor necrosis factor alpha (TNFα), 
interleukin 12p70 (IL-12p70), vascular endothelial growth 
factor (VEGF) and interleukin 13 (IL-13) were analyzed 
in accordance with manufacturer’s instructions (Bioplex 
cytokine assay; Bio-Rad Laboratories). A number of samples 
within each group were out of range for some of the 
analytes tested, these include the following: plasminogen 
activator inhibitor 1 (PAI-1), granulocyte colony 
stimulating factor (G-CSF), granulocyte macrophage 
colony stimulating factor (GM-CSF) and interleukin 7 
(IL-7). Plasma concentrations of aspartate aminotransferase 
(AST), alanine transaminase (ALT) and albumin (Randox 
Laboratories Ltd, Crumlin, County Antrem, UK) were 
analyzed at the University of Melbourne Veterinary 
Hospital (Werribee, Victoria, Australia) in accordance with 
manufacturer’s instructions.
Western blotting
Protein was isolated as described previously (38, 
39). Aliquots (40–100 μg) of the protein lysates were 
separated on a 7.5–20% SDS-PAGE gel and transferred to 
a nitrocellulose membrane. GPR55 (Novus Biologicals, 
Littleton, CO, USA), TGF-β1 (Abcam), collagen IV 
Table 2 Comparison of nutritional composition of diets.
Nutritional composition High-fat diet (SF00-219) Standard chow diet
Protein 19.0% 20%
Total fat 21.0% 5%
Crude fiber 4.7% 5%
Digestible energy 19.4 MJ/kg 17.25 MJ/kg
% Total calculated digestible energy from lipids 40.0% 10.7%
% Total calculated digestible energy from proteins 17.0% 19.7%
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(Abcam), VEGF (Abcam) and β-actin (Sigma Aldrich) were 
detected using Western blot analysis from kidney lysate 
using specific antibodies. Secondary anti-mouse and anti-
rabbit antibodies were purchased from Sigma Aldrich. 
Band densitometry was analyzed using Image Lab software 
(Bio-Rad Laboratories).
Statistical analysis
The statistical package GraphPad 7.00 Prism Software 
was used to generate graphs and to perform all statistical 
analysis. All data are presented as mean ± s.e.m. Normality 
of data sets were determined using Sharipo–Wilk 
normality test. Differences between treatment groups 
were individually analyzed and compared to the DIO 
control group using either an independent t-test or 
Mann–Whitney U test for two group direct analyses. 
Alternatively a two-way ANOVA and a Bonferroni’s 
multiple comparisons test was used for measurements 
that contain more than one time point. Significance was 
accepted when P < 0.05.
Results
Physiological effects
In our DIO rat model, we had previously reported that 
rats fed a HFD for 9 weeks had a significantly greater body 
weight and body fat percentage when compared with 
rats fed a chow diet (33), indicating that the rats utilized 
in these experiments were all DIO prior to treatment. 
The body weight (grams) for both pharmacological 
treatment groups were not altered when compared 
with the DIO control group (Fig.  1A), however the 
body weight of the DIO + O-1602-treated rats (% weight 
change from baseline of DIO) was reduced from weeks 
2 to 6 of the treatment period, while the body weight 
(% change from baseline of DIO) of the DIO + O-1918-
treated rats was not significantly altered (Fig.  1B). In 
terms of body composition, the body fat percentage 
was reduced at weeks 3 and 6 and lean tissue mass was 
increased at week 6 for the DIO + O-1602-treated rats, 
but not significantly altered for the DIO + O-1918-
treated group over the entire treatment period (Fig. 1D 
and E). Food intake was transiently reduced in the first 
week of treatment for the DIO + O-1602 group only 
(Fig. 1C). Blood pressure was not affected by treatment 
(Table  3). Glucose tolerance and insulin sensitivity all 
remained unchanged across all the treatment groups 
when compared to DIO + control (Fig.  1F, G, H and I  
and Table 3).
Effects on organ weights
The DIO + O-1602-treated group had reduced epididymal 
fat depots when compared with the DIO control group, 
there was also a nonsignificant trend (P = 0.077, total mass 
and P = 0.074, percentage of body weight) for peri-renal fat 
pad depots to be reduced (Table 4). These findings support 
the observations of a reduction in body fat percentage, 
while brown adipose tissue (BAT) depots were not altered 
by treatment with this compound. There was also an 
increase in kidney and liver mass in the DIO + O-1602-
treated group while heart mass was unaffected by the 
chronic treatment (Table 4).
The DIO + O-1918-treated group had reduced BAT 
depots when compared with the DIO control group. Other 
tissues, including WAT epididymal and peri-renal fat pads, 
liver, kidney and heart mass, were not altered by chronic 
treatment with O-1918 in this DIO model (Table 4).
Effects on circulating plasma hormones 
and cytokines
The plasma hormone analysis shows that DIO rats treated 
with O-1602 or O-1918 had reduced circulating leptin 
and ghrelin concentrations when compared to the DIO 
control group. Conversely other hormones including 
glucagon, GLP-1 and adiponectin plasma concentrations 
were not altered by either of the pharmacological 
treatments (Table 5).
The plasma cytokine analysis shows DIO + O-1602-
treated rats had a nonsignificant trend for RANTES to be 
increased (P = 0.0981), while all of the other cytokines 
were not altered when compared to the DIO + control 
group (Table 5). The plasma cytokine analysis also shows 
that DIO + O-1918-treated rats had increased plasma 
pro-inflammatory cytokines when compared to the 
DIO + control group, including IL-1α, IL-2, IL-17α, IL-18 
and RANTES. There was also a nonsignificant trend for 
EPO to be increased (P = 0.056).
Effects on renal structure and function
We have shown for the first time that GPR55 is 
significantly increased in whole kidney tissue samples 
of DIO rats after 10 weeks of high-fat feeding (Fig. 2A). 
Histological analysis showed that treatment with 
O-1602 did not affect glomerular area or tubular 
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cross-sectional diameter (Fig. 2B, C and D). Treatment 
with O-1918 did exhibit significantly reduced tubular 
cross-sectional area compared to DIO controls 
(Fig.  2B, C and D). No significant changes, however, 
were observed in the renal fibrotic markers collagen IV, 
TGF-β1 or VEGF protein in DIO rats treated with 
either O-1602 or O-1918 compared to DIO controls 
(Fig. 2E, F, G and H).
Figure 1
Physiological outcomes obtained from rats fed a high-fat diet for 9 weeks to induce obesity, then the diet-induced obese (DIO) rats were allocated to one of 
three treatment groups based on their characteristics including weight, body composition, blood pressure, glucose tolerance and insulin sensitivity and then 
treated with either a vehicle (DIO control) (n = 11), O-1602 (DIO O-1602) (n = 6) or O-1918 (DIO O-1918) (n = 9) for a period of 6 weeks. (A) Body weight (grams) 
for both DIO and the treatment period. (B) Weight change (% from baseline DIO) over the treatment period. (C) Food consumption (grams) for both DIO and 
the treatment period. (D) Body fat % over the treatment period and (E) lean body mass % over the treatment period. (F) ip. GTT blood glucose levels (mmol/L) 
at week 8 prior to treatment. (G) ip. GTT blood glucose levels (mmol/L) at week 14 following treatment. (H) ip. IST blood glucose levels (mmol/L) at week 8 prior 
to treatment. (I) ip. IST blood glucose levels (mmol/L) at week 14 following treatment. Data was analyzed using a two tailed t-test to compare the DIO + control 
group to either the DIO + O-1602 group (*significance P < 0.05) or the DIO + O-1918 group (#significance P < 0.05). Data is represented as group average ± s.e.m.
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In DIO rats treated with either O-1602 or O-1918, 
urinary albumin excretion (Fig.  2I) was significantly 
reduced compared to DIO controls. No significant changes 
in plasma creatinine (Fig.  2J) or estimated creatinine 
clearance (Fig. 2K) were observed in DIO rats treated with 
either O-1602 or O-1918 compared to DIO controls.
Effects on hepatic function
Livers from DIO + O-1602-treated rats had abnormal 
and dark appearing pigments when compared to the 
DIO + control group (Fig. 3A and B). As a result of these 
abnormal and dark appearing pigments and the need 
to euthanize one rat within the DIO + O-1602 treatment 
group (one rat was removed from all analysis leaving n = 6) 
as a result of ongoing diarrhea and rapid weight loss, no 
further animals were treated with O-1602. Despite these 
observations fibrotic marker hydroxyproline, which is a 
component of liver and cardiac collagen content in the 
DIO + O-1602-treated group, was not altered in either 
tissue (Fig. 3B and C). Plasma liver function test indicated 
a nonsignificant trend for AST to be increased (P = 0.078) 
Table 3 The effect that chronic administration of either O-1602 or O-1918 have on physiological outcomes (pre- and 
posttreatment) in a diet-induced obese rat model.
Measurement
Treatment groups
DIO control DIO O-1602 DIO O-1918
Pretreatment Posttreatment Pretreatment Posttreatment Pretreatment Posttreatment
Weight (g) 592 ± 13 667 ± 17 605 ± 22 624 ± 27 604 ± 21 664 ± 21
Food consumption (g) 23.5 ± 1.1 21.7 ± 0.5 23.0 ± 1.2 22.2 ± 1.2 22.5 ± 0.9 20.8 ± 0.8
Total body fat mass (%) 17.2 ± 1.2 20.0 ± 1.6 15.0 ± 1.1 13.8 ± 1.5* 17.7 ± 1.4 19.0 ± 1.5
Total lean body mass (%) 77.1 ± 1.5 75.8 ± 1.5 81.3 ± 1.2 81.9 ± 1.6* 78.1 ± 1.4 77.1 ± 1.6
Diastolic blood pressure (mmHg) 105 ± 6 (n = 10) 105 ± 5 116 ± 72 114 ± 8 94 ± 4.3 (n = 8) 95 ± 3 (n = 6)
Systolic blood pressure (mmHg) 141 ± 4 (n = 10) 144 ± 5 159 ± 8 157 ± 9 133 ± 4 (n = 8) 140 ± 1 (n = 6)
Glucose tolerance (delta AUC) 565 ± 73 613 ± 85 473 ± 88 600 ± 70 542 ± 67 (n = 8) 504 ± 58
Insulin sensitivity (delta AUC) 212 ± 31 205 ± 43 130 ± 39 198 ± 34 126 ± 29 128 ± 26
KITT (%/m) 0.9 ± 0.1 0.8 ± 0.2 0.8 ± 0.1 1.0 ± 0.2 0.6 ± 0.1 0.7 ± 0.1
t½ (min) 93 ± 14 149 ± 54 94 ± 13 100 ± 28 143 ± 36 116.6 ± 17.4
Maximal decline of glucose 3.7 ± 0.3 3.5 ± 0.5 4.3 ± 0.6 2.9 ± 0.3 4.3 ± 0.2 3.4 ± 0.2
Physiological outcomes were obtained from rats fed a high-fat diet for 9 weeks to induce obesity, then the diet-induced obese (DIO) rats were treated 
with either a vehicle (DIO control) (n = 11), O-1602 (DIO O-1602) (n = 6) or O-1918 (DIO O-1918) (n = 9) for a period of 6 weeks. Where data points were 
missing the specific n value is included on table next to the mean value for that measurement and group. After determining the normality of each data 
set, data was analyzed using either a two tailed t-test or Mann–Whitney U test to compare the DIO + control group to either the DIO + O-1602 group or 
the DIO + O-1918 group (*significance P < 0.05). Data is represented as average ± s.e.m. Bold indicates statistical significance.
Table 4 The effect that chronic administration of either O-1602 or O-1918 has on organ weights in a diet-induced obese rat 
model.
Measurement
Treatment groups
DIO control DIO O-1602 DIO O-1918
Body weight at time of death (grams) 680 ± 20 632 ± 27 669 ± 20
Heart mass (grams) 1.7 ± 0.1 (n = 7) 1.7 ± 0.1 1.6 ± 0.1
Heart mass/body weight (%) 0.3 (n = 7) 0.3 0.2
Kidney mass (grams) 1.7 ± 0.1 2.0 ± 0.1* 1.6 ± 0.1
Kidney mass/body weight (%) 0.3 0.3* 0.3
Epididymal fat pad mass (grams) 10.8 ± 0.8 7.4 ± 0.7* 8.8 ± 0.8
Epididymal fat pad mass/body weight (%) 1.6 ± 0.1 1.2 ± 0.1* 1.3 ± 0.1
Peri-renal fat pad mass (grams) 12.7 ± 1.3 9.1 ± 0.8 12.2 ± 1.3
Peri-renal fat pad mass/body weight (%) 1.8 ± 0.1 1.4 ± 0.1 1.8 ± 0.2
Brown fat pad mass (grams) 1.1 ± 0.1 (n = 10) 0.8 ± 0.1 0.8 ± 0.1*
Brown fat pad mass/body weight (%) 0.2 (n = 10) 0.1 0.1*
Liver mass (grams) 23.1 ± 1.0 23.5 ± 0.9 23.2 ± 1.4
Liver mass/body weight (%) 3.4 ± 0.1 3.7 ± 0.1* 3.5 ± 0.2
Organs were obtained from rats fed a high-fat diet for 9 weeks to induce obesity, then the diet-induced obese (DIO) rats were treated with either a 
vehicle (DIO control) (n = 11), O-1602 (DIO O-1602) (n = 6) or O-1918 (DIO O-1918) (n = 9) for a period of 6 weeks. Where organ weights for data sets were 
missing the specific n value is included on table next to the mean organ weight for that group. After determining the normality of each data set, data was 
analyzed using either a two tailed t-test or Mann–Whitney U test to compare the DIO + control group to either the DIO + O-1602 group or the 
DIO + O-1918 group (*significance P < 0.05). Data is represented as average ± s.e.m. Bold indicates statistical significance.
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in the DIO + O-1602-treated group when compared to 
controls, while circulating ALT and albumin were not 
altered. DIO + O-1918-treated rats had no visual difference 
in liver appearance when compared to the DIO + control 
group (Fig. 3A and C). Circulating plasma concentration 
of AST was increased while ALT and albumin were 
not altered.
Discussion
Our study is the first to investigate O-1602 or O-1918 and 
their effects on whole body energy homeostasis, renal and 
hepatic function in a DIO rat model. For the first time we 
showed in DIO rats that GPR55 expression was elevated 
in renal tissue. Research focusing on GPR55 in obesity 
shows that GPR55 expression is significantly greater in 
the adipose tissue of obese humans when compared with 
lean individuals (40), these data are consistent with our 
observations of GPR55 expression in the DIO rat kidney 
compared to chow-fed controls. Recently, GPR55 has 
been shown to be expressed in skeletal muscle of rat and 
human, the same research group concluded that GPR55 
is a positive regulator of insulin action and adipogenesis 
(41). These finding were consistent with Meadows et al. 
(57) that previously had found that GPR55 knockout 
mice have increased insulin resistance and adiposity as a 
result of reduced physical activity but had not confirmed 
expression in the skeletal muscle. Further, rats fed a low 
fat diet have greater GPR55 expression in white adipose 
tissue when compared with HFD fed rats, although the 
duration in which the diets were consumed is unclear. 
Therefore GPR55 expression appears to vary depending 
on species, dietary intake and tissue type, and may also 
be a beneficial therapeutic target for obesity-related 
comorbidities such as type 2 diabetes mellitus.
Table 5 The effect that chronic administration of either O-1602 or O-1918 has on either circulating plasma hormones or 
cytokines in a diet-induced obese rat model.
Analyte DIO Control DIO O-1602 DIO O-1918
Hormones
 Glucagon (pg/mL) 345 ± 50 241 ± 42 291 ± 58
 GLP-1 (pg/mL) 236± 76 119 ± 45 319 ± 99 (n = 8)
 Ghrelin (ng/mL) 4 ± 0.4 2 ± 0.2* 2 ± 0.2*
 Leptin (ng/mL) 10 ± 1 3 ± 0.4* 6 ± 1*
 Adiponectin (µg/mL) 11 ± 0.8 12 ± 2 12 ± 1
Cytokines
 EPO (pg/mL) 826 ± 165 1263 ± 322 1675 ± 439
 GRO/KC(pg/mL) 254 ± 76 (n = 10) 367 ± 68 213 ± 36
 IFN-γ (pg/mL) 446 ± 177 (n = 8) 578 ± 163 (n = 5) 664 ± 184
 IL-1α (pg/mL) 170 ± 48 (n = 10) 300 ± 88 459 ± 129*
 IL-1β (ng/mL) 6 ± 2 8 ± 3 10 ± 3
 MCP-1 (ng/mL) 1 ± 0.2 (n = 9) 1 ± 0.1 1 ± 0.2
 IL-2 (pg/mL) 341 ± 71 588 ± 149 860 ± 201*
 IL-4 (pg/mL) 230 ± 72 337 ± 86 456 ± 108
 IL-5 (pg/mL) 373 ± 71 527 ± 124 521 ± 94
 IL-6 (pg/mL) 276 ± 108 (n = 9) 427 ± 112 (n = 5) 606 ± 217
 IL-10 (ng/mL) 1 ± 0.4 1 ± 0.3 2 ± 0.4
 IL-17α (pg/mL) 114 ± 30 203 ± 53 271 ± 48*
 IL-18 (ng/mL) 4 ± 1 7 ± 3 8.0 ± 1.8*
 MC-SF (pg/mL) 504 ± 34 423 ± 29 449 ± 43
 MIP-3α (pg/mL) 118 ± 29 140 ± 30 190 ± 33
 RANTES (pg/mL) 297 ± 64 520 ± 126 724 ± 78*
 TNFα (pg/mL) 185 ± 60 204 ± 52 270 ± 61 (n = 8)
 IL-12p70 (pg/mL) 276 ± 90 470 ± 166 521 ± 154 (n = 8)
 VEGF (pg/mL) 67 ± 22 80 ± 27 103 ± 30
 IL-13 (pg/ mL) 108 ± 34 140.4 ± 46 203 ± 51 (n = 8)
 TGFβ (ng/mL) 18 ± 3 (n = 8) 17 ± 2 20 ± 2 (n = 7)
Blood/plasma was obtained from rats fed a high-fat diet for 9 weeks to induce obesity, then the diet-induced obese (DIO) rats were treated with either a 
vehicle (DIO control) (n = 11), O-1602 (DIO O-1602) (n = 6) or O-1918 (DIO O-1918) (n = 9) for a period of 6 weeks. When data sets were out of range the 
changed n value is included on table next to the mean concentration for that group. After determining the normality of each data set, data was analyzed 
using either a two tailed t-test or Mann–Whitney U test to compare the DIO + control group to either the DIO + O-1602 group or the DIO + O-1918 group 
(*significance P < 0.05). Data is represented as average ± s.e.m. Bold indicates statistical significance.
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Further, O-1602 treatment in this DIO model had 
significant effects on several metabolic parameters, 
including reduced weight gain (% weight change from 
baseline) and body fat %, increased lean mass and a 
transient reduction in food intake. Our findings clearly 
indicate that O-1602 has a role in metabolic homeostasis. 
Previous research in a lean Sprague–Dawley model 
administered O-1602 at a lower dosage and for a shorter 
Figure 2
Renal structure and function obtained from rats fed a high-fat diet (HFD) for 9 weeks to induce obesity, then diet-induced obese (DIO) rats were treated 
with either a vehicle (DIO control) (n = 11), O-1602 (DIO O-1602) (n = 6) or O-1918 (DIO O-1918) (n = 9) for a period of 6 weeks or GPR55 expression in rats 
fed either a HFD (n = 8) or standard chow diet (chow) (n = 8) for 10 weeks. (A) Kidney protein expression of GPR55 increased in rats fed a HFD to induce 
obesity (DIO) (n = 8) compared to chow-fed for 10 weeks (n = 8). (B) H&E staining of glomerular and tubular cross-sectional areas shown at 200× 
magnification. (C) Quantification of tubular cross-sectional area (µm). (D) Quantification of glomerular cross-sectional area (µm2). (E) Western blots of 
fibrotic markers in kidney tissue. (F) Collagen IV expression in kidney tissue. (G) TGF-β expression in kidney. (H) VEGF expression in kidney. (I) Change in 
urinary albumin excretion (μg/mL). (J) Change in plasma creatinine concentration. (K) Estimated creatinine clearance, posttreatment (mg/mL/kg). Data 
was analyzed using a two tailed t-test to compare the DIO + control group to either the DIO + O-1602 group (*significance P < 0.05) or the DIO + O-1918 
group (#significance P < 0.05). Data is represented as group average ± s.e.m.
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timeframe than our study (0.1–1 mg/kg for 1 week) found 
no reduction in food intake or body weight and increased 
body fat mass (32). Further, an acute dose of O-1602 
(200 μg/kg, IP) administered to GPR55 knockout mice 
increased food intake (32) suggesting this compound 
may elicit effects on receptor(s) other than GPR55 such 
as GPR18 (21, 42). In addition to the reduced body fat 
observed in the DIO + O-1602-treated rats, the reduced 
body weight could also be reflective of alterations in the 
functioning of various other tissues due to the expression 
profiling of receptors targeted by O-1602, including 
GPR55 which has been demonstrated to alter transit 
time and expressed in the myenteric neurons in the 
colon (43, 44).
In contrast to the O-1602 treatment, O-1918 treatment 
in DIO rats did not alter a range of metabolic measures, but 
did reduce BAT mass when compared to the DIO + control 
group. Two hormones involved in regulating food intake; 
leptin and ghrelin were both decreased in response to 
treatment with O-1602 and O-1918. Leptin and ghrelin 
have opposing roles on food intake and appetite control; 
leptin induces satiety, while ghrelin increases appetite 
(45). Obesity is accompanied by a dysregulation in 
leptin signaling where hyperleptinemia (46) and leptin 
resistance (47) are evident. We have previously shown 
in this model of obesity that DIO + control treated rats 
had increased circulating plasma leptin concentrations 
compared to chow-fed control rats (48). Both leptin and 
ghrelin concentrations are influenced by food intake 
(49, 50) and the release of ghrelin is produced during the 
fast state and inhibited during the fed state (50), whereas 
leptin secretion is promoted during food intake and in 
the fed state and is decreased during starvation (49). 
Plasma leptin concentrations reflect total adipose tissue 
stores (51). The DIO + O-1602-treated rats had reduced 
epididymal fat pad mass and total body fat percentage 
which reflects total adipose tissue store, this potentially 
explains the decreased circulating leptin concentrations 
observed in the DIO + O-1602 group of rats. A relationship 
between cannabinoids and leptin exists (52), with 
mRNA expression of GPR55 increasing following leptin 
administration in starved rodents, reverting the GPR55 
mRNA expression levels back to the same concentrations 
as rats with ad libitum access to chow-fed (53). The 
interaction between leptin and GPR55 could influence 
leptin plasma concentrations with O-1918 treatment. 
Despite the alterations in leptin and ghrelin, no alterations 
in GLP-1, glucagon and adiponectin were observed.
This study is first to look at the effect of O-1602 and 
O-1918 on several circulating cytokines and chemokines 
in DIO. Cytokines and chemokines were not significantly 
altered following O-1602 treatment. However, O-1918 
treatment in DIO increased pro-inflammatory cytokines 
including IL-1α, IL-2, IL-17α, IL-18 and RANTES. The 
DIO + O-1918-treated rats had reduced BAT depots 
compared with the DIO control rats. In DIO rodents, 
blocking CB1 increases temperature of BAT and 
upregulates UCP-1 (54). In this study, we measured BAT 
deposits but changes in function of this tissue with the 
treatment of O-1918 were not investigated. Increased pro-
inflammatory cytokines (associated with the development 
of insulin resistance), accompanied by the decrease in BAT 
could be interrelated. Over-activity of pro-inflammatory 
cytokines can lead to dysfunction and apoptosis in brown 
adipocytes in a murine cell culture model mediated by 
UCP-1 and β-Klotho suppression (55). Rebiger et al. (55) 
investigated pro-inflammatory cytokines IL-1β, TNFα and 
IFN-γ, which contrasts with our results as these cytokines 
were not altered. However, as administration of O-1918 in 
DIO increased several other pro-inflammatory cytokines 
these cytokines may have contributed to apoptosis in the 
BAT; however, further investigation is required to elucidate 
this. O-1918 in DIO did not alter glucose tolerance or 
insulin sensitivity in our study; however, the rats were not 
Figure 3
Liver or heart analysis obtained from rats fed a high-fat diet for 9 weeks to induce obesity, then the diet-induced obese (DIO) rats were treated with 
either a vehicle (DIO control) (n = 8), O-1602 (DIO O-1602) (n = 6) or O-1918 (DIO O-1918) (n = 9) for a period of 6 weeks. (A) Representative picture of 
DIO + control, DIO + O-1602 and DIO + O-1918-treated whole liver. (B) Liver collagen concentration. (C) Heart collagen concentration. (D) Plasma 
concentration of liver function analytes. Data was analyzed using a two tailed t-test to compare the DIO control group to either the DIO + O-1602 group 
(*significance P < 0.05) or the DIO + O-1918 group (#significance P < 0.05). Data is represented as group average ± s.e.m.
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glucose intolerant or insulin resistant as a result of the 
HFD used (33), which is in line with previous research (56). 
Therefore, the effect that O-1918 had on impaired glucose 
homeostasis could not be assessed in this model; however, 
our plasma results suggest that O-1918 does not impair 
glucose tolerance or insulin sensitivity. GPR55 knockout 
mice have increased adiposity and insulin resistance (57), 
given that O-1918 is a putative antagonist for GPR55 
and that obesity and insulin resistance are associated 
with chronic low-grade inflammation (58, 59), this could 
account for the increased circulating pro-inflammatory 
cytokines observed in this study.
O-1602 treatment significantly reduced urinary 
albumin, in conjunction with abrogation of weight 
gain. Plasma creatinine, creatinine clearance or cytokine 
profile in renal tissue were not altered in DIO + O-1602 or 
O-1918-treated rats. The reduced weight gain observed 
in our model of DIO + O-1602-treated rats potentially 
mediated the significant improvements in kidney 
function, including reduced urinary albumin. Histological 
examination showed no signs of structural alterations to 
the kidney induced by treatment with O-1602 compared to 
DIO + controls and the renal cytokine profile was also not 
altered. Both gross kidney weight and kidney weight as a 
percentage of total body weight were significantly higher 
in O-1602+DIO rats. Improved albuminuria in O-1602-
treated rats may be independent of structural changes to 
the kidney (particularly as no changes to tubular diameter 
or glomerular area was detected in DIO + O-1602-treated 
rats), as male Wistar rats infused with leptin showed 
increased proteinuria and albuminuria (60). Significant 
reduction in weight gain exhibited by DIO + O-1602-
treated rats occurred concurrently with reduced circulating 
plasma leptin concentrations. Although the mechanism 
of leptin-induced proteinuria has yet to be elucidated, it 
is postulated that changes to proteinuria in leptin-infused 
animals may be caused by increased renal expression of 
TGF-β1 (60, 61). As DIO + O-1602-treated rats in our study 
showed no changes to renal cytokine profile, including 
renal expression of TGF-β1, it is unlikely that O-1602 
mediates improved albuminuria via this pathway.
This study demonstrated that treatment with O-1918 
leads to significant reductions in urinary albumin 
excretion and reduced renal tubular diameter compared 
to DIO + controls. These improvements occurred in 
the absence of reduced weight gain; however, as with 
the O-1602 treatment, circulating plasma leptin was 
significantly reduced compared to DIO + controls. This 
occurred in conjunction with no significant changes to 
gross kidney weight; however, a significant reduction 
in renal tubular diameter was observed. Previously, 
we identified that renal tubular cross-sectional area is 
significantly greater in rats with DIO after 10  weeks 
compared to lean chow-fed rats (48). Alterations to 
renal tubular architecture by treatment with O-1918 
may contribute to reduced albumin urinary excretion 
in rats with DIO. Studies examining renal hypertrophy 
under pathophysiological conditions focus on protein 
synthesis; however, increased expression of collagen, 
TGF-β1, collagen IV and VEGF expression were not altered 
in this study. Hypertrophy may also emanate from a 
decrease in protein catabolism (62); however, exploring 
the process of protein breakdown in tubular cells was 
beyond the scope of this study but may be a mechanism 
by which O-1918 regulates renal hypertrophy. Other 
measures of renal function including plasma creatinine 
and estimated creatinine clearance were not altered with 
either treatment.
In DIO + O-1602-treated rats, the hepatic morphology 
observed suggests that this compound elicits undesirable 
effects, while DIO + O-1918 treated rats had similar liver 
morphology to DIO + controls. Currently, no studies 
have investigated the effects of O-1602 in the liver in 
DIO and therefore further investigation is required. Our 
data indicates that O-1602 causes an enlarged liver with 
abnormal dark pigmentation, and a nonsignificant trend 
for increased plasma AST, while other markers of liver 
function (ALT, albumin) were not altered. AST and ALT 
are both markers of hepatocyte integrity (63), while AST is 
also found in non-hepatic tissues, it is highly concentrated 
in the liver (63). Since the fibrotic marker hydroxyproline 
in both the liver and heart tissue was not altered in the 
DIO + O-1602-treated rats, this suggests that O-1602 is not 
causing fibrosis. Therefore, further investigation into the 
causes of the changes in liver morphology is required.
In conclusion, this study has for the first time focused 
on the role of atypical cannabinoid ligands O-1602 and 
O-1918 as therapeutics in obesity. These compounds 
attenuate some aspects of metabolic dysfunction associated 
with obesity. While O-1602 had beneficial effects on 
whole body composition and reduced albuminuria in 
obesity, the compound appeared to have adverse side 
effects particularly in the liver suggesting O-1602 may not 
be a suitable compound as an anti-obesity pharmaceutical 
at the dosage utilized in this study. Future research should 
focus on the G Protein-Coupled Receptors that O-1602 
targets (such as GPR55 and GPR18) as modulating these 
receptors using different ligands may be of benefit when 
targeting specific tissues such as the adipose tissue or the 
kidney to help overcome the adverse effects observed with 
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O-1602 treatment in this study. While O-1918 reduced 
BAT mass it did not alter total body fat or lean tissue mass, 
the compound did however help reduce albuminuria 
and reduced renal tubular hypertrophy. This study 
shows for the first time that O-1918 may be beneficial 
for ameliorating the renal structural and functional 
damage which occurs in response to a HFD. Therefore 
O-1918 maybe a beneficial compound in the treatment of 
obesity-related kidney disease. Further investigation into 
the mechanisms of action of O-1602 and O-1918 in the 
DIO state is required.
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